Absence of IL-12RΒ2 in CD33 + CD38 + pediatric acute myeloid leukemia cells favours progression in NOD/SCID/IL2RγC- deficient mice

Leukemia

Volumn 26, Issue 2, 2012, Pages 225-235

  Ferretti, E ^a   Montagna, D ^b   Di Carlo, E ^c   Cocco, C ^a   Ribatti, D ^d   Ognio, E ^e   Sorrentino, C ^c   Lisini, D ^f   Bertaina, A ^g   Locatelli, F ^b,g   Pistoia, V ^a   Airoldi, I ^a  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

^d UNIVERSITY OF BARI   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

^f FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^g BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

AML; cytokine receptor; cytokines

Indexed keywords

CD33 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN; CD44V ANTIGEN; CD45 ANTIGEN; INTERLEUKIN 12 RECEPTOR BETA1; INTERLEUKIN 12 RECEPTOR BETA2; RECOMBINANT INTERLEUKIN 12;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLAST CELL; CANCER GROWTH; CELL POPULATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG BINDING; ENGRAFTMENT; FEMALE; HUMAN; HUMAN CELL; INFANT; INOCULATION; LEUKEMIA CELL; MALE; METASTASIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SPLEEN; T LYMPHOCYTE; TUMOR CELL; TUMOR LOCALIZATION;

ADOLESCENT; ADULT; ANIMALS; ANTIGENS, CD; ANTIGENS, CD38; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CELL DIVISION; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FEMALE; FLOW CYTOMETRY; HUMANS; INFANT; INTERLEUKIN-12 RECEPTOR BETA 2 SUBUNIT; LEUKEMIA, MYELOID, ACUTE; MALE; MICE; MICE, INBRED NOD; MICE, SCID; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84856751793     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.213     Document Type: Article

References (47)

1. Stone RM, O'Donnell MR, Sekeres MA. Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2004; 1: 98-117.
2. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292-2302.
3. Kaspers GJ, Zwaan CM. Pediatric acute myeloid leukemia: towards high-quality cure of all patients. Haematologica 2007; 92: 1519-1532. (Pubitemid 350144128)
4. Shah M, Agarwal B. Recent advances in management of acute myeloid leukemia (AML). Indian J Pediatr 2008; 75: 831-837.
5. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-737. (Pubitemid 27298715)
6. Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 2004; 5: 738-743. (Pubitemid 39023306)
7. Dick JE. Acute myeloid leukemia stem cells. Ann NY Acad Sci 2005; 1044: 1-5. (Pubitemid 40967588)
8. Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 2007; 25: 1315-1321. (Pubitemid 350076512)
9. Lane SW, Scadden DT, Gilliland DG. The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood 2009; 114: 1150-1157.
10. Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality? Nat Med 2009; 15: 1010-1012
11. Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 2009; 8: 806-823.
12. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645-648. (Pubitemid 24067706)
13. Mansson R, Hultquist A, Luc S, Yang L, Anderson K, Kharazi S et al. Molecular evidence for hierarchical transcriptional lineage priming in fetal and adult stem cells and multipotent progenitors. Immunity 2007; 26: 407-419. (Pubitemid 46603001)
14. Taussig DC, Miraki-Moud F, Anjos-Afonso F, Pearce DJ, Allen K, Ridler C et al. Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood 2008; 112: 568-575.
15. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2006; 12: 1167-1174. (Pubitemid 44527352)
16. Jin L, Lee EM, Ramshaw HS, Busfield SJ, Peoppl AG, Wilkinson L et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 2009; 5: 31-42.
17. Sarry JE, Murphy K, Perry R, Sanchez PV, Secreto A, Keefer C et al. Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rgammacdeficient mice. J Clin Invest 2011; 121: 384-395.
18. Presky DH, Yang H, Minetti LJ, Chua AO, Nabavi N, Wu CY et al. A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits. Proc Natl Acad Sci USA 1996; 93: 14002-14007.
19. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3: 133-146. (Pubitemid 37328691)
20. Wolf SF, Temple PA, Kobayashi M, Young D, Dicig M, Lowe L et al. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol 1991; 146: 3074-3081.
21. Airoldi I, Cocco C, Giuliani N, Ferrarini M, Colla S, Ognio E et al. Constitutive expression of IL-12R beta 2 on human multiple myeloma cells delineates a novel therapeutic target. Blood 2008; 112: 750-759.
22. Airoldi I, Di Carlo E, Cocco C, Caci E, Cilli M, Sorrentino C et al. IL-12 can target human lung adenocarcinoma cells and normal bronchial epithelial cells surrounding tumor lesions. PLoS One 2009; 4: e6119.
23. Airoldi I, Di Carlo E, Cocco C, Taverniti G, D0Antuono T, Ognio E et al. Endogenous IL-12 triggers an antiangiogenic program in melanoma cells. Proc Natl Acad Sci USA 2007; 104: 3996-4001. (Pubitemid 47181567)
24. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993; 178: 1223-1230. (Pubitemid 23277355)
25. Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S, Stein H et al. WHO Classification of Tumors. IARC: Lyon, 2008.
26. Montagna D, Locatelli F, Moretta A, Lisini D, Previdere C, Grignani P et al. T lymphocytes of recipient origin may contribute to the recovery of specific immune response toward viruses and fungi in children undergoing cord blood transplantation. Blood 2004; 103: 4322-4329. (Pubitemid 38685380)
27. Allen RC, Graves G, Budowle B. Polymerase chain reaction amplification products separated on rehydratable polyacrylamide gels and stained with silver. Biotechniques 1989; 7: 736-744. (Pubitemid 19212399)
28. Airoldi I, Di Carlo E, Banelli B, Moserle L, Cocco C, Pezzolo A et al. The IL-12Rbeta2 gene functions as a tumor suppressor in human B cell malignancies. J Clin Invest 2004; 113: 1651-1659. (Pubitemid 39071689)
29. Airoldi I, Di Carlo E, Cocco C, Sorrentino C, Fais F, Cilli M et al. Lack of Il12rb2 signaling predisposes to spontaneous autoimmunity and malignancy. Blood 2005; 106: 3846-3853. (Pubitemid 41739022)
30. Agliano A, Martin-Padura I, Mancuso P, Marighetti P, Rabascio C, Pruneri G et al. Human acute leukemia cells injected in NOD/ LtSz-scid/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains. Int J Cancer 2008; 123: 2222-2227.
31. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature 2008; 456: 593-598.
32. Akashi K, Harada M, Shibuya T, Eto T, Takamatsu Y, Teshima T et al. Effects of interleukin-4 and interleukin-6 on the proliferation of CD34+ and CD34-blasts from acute myelogenous leukemia. Blood 1991; 78: 197-204.
33. Avigdor A, Goichberg P, Shivtiel S, Dar A, Peled A, Samira S et al. CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+ stem/progenitor cells to bone marrow. Blood 2004; 103: 2981-2989. (Pubitemid 38451670)
34. Naor D, Wallach-Dayan SB, Zahalka MA, Sionov RV. Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin Cancer Biol 2008; 18: 260-267.
35. Quere R, Andradottir S, Brun AC, Zubarev RA, Karlsson G, Olsson K et al. High levels of the adhesion molecule CD44 on leukemic cells generate acute myeloid leukemia relapse after withdrawal of the initial transforming event. Leukemia 2011; 25: 515-526.
36. Morisot S, Wayne AS, Bohana-Kashtan O, Kaplan IM, Gocke CD, Hildreth R et al. High frequencies of leukemia stem cells in pooroutcome childhood precursor-B acute lymphoblastic leukemias. Leukemia 2010; 24: 1859-1866.
37. Hauswirth AW, Florian S, Printz D, Sotlar K, Krauth MT, Fritsch G et al. Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells. Eur J Clin Invest 2007; 37: 73-82. (Pubitemid 44934775)
38. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 351: 1860-1873.
39. Roodman GD. Role of the bone marrow microenvironment in multiple myeloma. J Bone Miner Res 2002; 17: 1921-1925. (Pubitemid 35239190)
40. Caunt M, Mak J, Liang WC, Stawicki S, Pan Q, Tong RK et al. Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell 2008; 13: 331-342. (Pubitemid 351446192)
41. Xu Y, Yuan L, Mak J, Pardanaud L, Caunt M, Kasman I et al. Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3. J Cell Biol 2010; 188: 115-130.
42. Bellone G, Trinchieri G. Dual stimulatory and inhibitory effect of NK cell stimulatory factor/IL-12 on human hematopoiesis. J Immunol 1994; 153: 930-937. (Pubitemid 24228483)
43. Chen T, Burke KA, Zhan Y, Wang X, Shibata D, Zhao Y. IL-12 facilitates both the recovery of endogenous hematopoiesis and the engraftment of stem cells after ionizing radiation. Exp Hematol 2007; 35: 203-213. (Pubitemid 46135811)
44. Gollob JA, Mier JW, Veenstra K, McDermott DF, Clancy D, Clancy M et al. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res 2000; 6: 1678-1692. (Pubitemid 30305060)
45. Halin C, Rondini S, Nilsson F, Berndt A, Kosmehl H, Zardi L et al. Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol 2002; 20: 264-269. (Pubitemid 34205419)
46. Mortarini R, Borri A, Tragni G, Bersani I, Vegetti C, Bajetta E et al. Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12. Cancer Res 2000; 60: 3559-3568. (Pubitemid 30482177)
47. Triozzi PL, Allen KO, Carlisle RR, Craig M, LoBuglio AF, Conry RM. Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma. Clin Cancer Res 2005; 11: 4168-4175. (Pubitemid 40791582)